ArticleNature communications2023

Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy.

Vipul Bhatia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.